Hamburg: Judge the agency on public health

Share this article:
FDA commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein said in a June 11 New England Journal of Medicine “Perspective” column that the “ultimate measure of FDA's success should reflect its fundamental goals and go beyond such intermediate measures as the number of facilities inspected or drugs approved.” They wrote that FDA's job is to support people's access to a safe food supply and to safe and effective medical products, and thus to promote health and prevent illness. As a public health agency, they said, FDA should always ask whether delays in approval can be prevented.

Hamburg and Sharfstein acknowledged that for medical products, FDA approval speed has been criticized as being either too fast or too slow, and say that a public health approach recognizes that the potential good of a new medical product or policy must be balanced against the potential harm. Some benefits are not worth the risk, but some risks are worth taking, they said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?